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FIG. 2. hNIS mRNA expression in tall-cell papillary thyroid
carcinoma. RT-PCR products were resolved on a 2% agarose gel

and visualized by ethidium bromide staining. PCR substrates are:
Lane 1, no cDNA (negative control); lane 2, normal thyroid (postive

control); lanes 3-7, tall-cell papillary thyroid carcinomas (samples
11~l5, Table l); and lane 8, GIBCO-BRL l kb-plus DNA ladder.
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FIG. 4. Re-expression of hNIS mRNA in thyroid cell lines.
Follicular adenoma cell line, KAKl (a). KAK-l cells were treated in
triplicates, with 5-azacytidine as described. The RT-PCR products
were resolved on a 2% agarose gel and visualized by ethidium
bromide staining. lanel. no cDNA; lane 2 to 4. untreated; lanes 5

to 7. 0.5 11M 5-azacytidine for 3 days (added each day); lanes 8 to 10.
1.0 11M 5-azacytidine for 3 days (added each day); lane 11. GIBCO
BRL 1 kb plus DNA ladder. Papillary carcinoma cell line, NPA'87
(b). NPA'87 cells were treated in triplicates, with sodium butyrate
or 5-azacytidine as described. The RT-PCR products were resolved
on a 2% agarose gel and visualized by ethidium bromide staining.

lanel. GIBCO-BRL 1 kb plus DNA ladder; lane 2. normal human
thyroid; lane 3 to 5. untreated; lanes 6 to 8. 1.0 mM sodium
butyrate for 3 days; lanes 9 to 11. 1.0 11M 5-azacytidine for 3 days

(added each day).
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FIG. 6. Methylation analysis of hNIS gene regions in cell
lines re-expressing hNIS mRNA. Products of methylation
speci?c-PCB analysis of sodium bisul?te modi?ed genomic DNA,

from thyroid cell lines, using two methylation-speci?c primer pairs
(MET for regions L and C) and two corresponding non—methylated
speci?c primer pair (UNMET for regions L and C) were
elecrophoresed on an agarose gel in adjacent lanes. In all gels,
lanes 1 and 22: GIBCO-BRL 1 kb plus DNA ladder; lanes 2 through
7: triplicate pairs of cell lines under basal conditions; lanes 8
through 19: triplicate pairs of cell lines in two different treatment
conditions; lanes 20 and 21: negative controls without template
DNA (all even numbered lanes contain the respective UNMET
products and odd numbered lanes contain the correponding MET
products). Cell line KAK-l studied with primer pairs speci?c for
region L (a). Treatment conditions in lanes 8-13 and lanes 14-19

include 5-azacytidine at 0.5 pM and 1.0 pM, respectively. Cell line

KAK-l studied with primer pairs speci?c for region C (b), with
conditions identical to (8.7. Cell line NPA'87 studied with primer

pairs speci?c for region L (c). Treatment conditions in lanes 8-13
and lanes 14-19 include sodium butyrate at 1.0 mM and 5

azacytidine at 1.0 11M, respectively. Cell line NPA'87 studied with
primer pairs speci?c for region C (d), with conditions identical to (c).

21
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IODINE UPTAKE RESTORATION IN
THYROID CANCER

that chemical agents may demethylate these regions and
restore gene expression. Examples include use of: 5-aZacy
tidine to restore expression of O6-methylguanine-DNA
methyltransferase in human cervical, brain, and colon car
cinomas (12,13); phenylacetate to induce fetal hemoglobin
expression in human leukemic cells (14); and sodium
butyrate to induce prolactin receptor expression in human

CONTINUING DATA

This application claims the bene?t of priority to US.

Provisional Application No. 60/140,976, ?led Jun. 29, 1999,
the contents of Which are incorporated herein by reference in

breast cancer cells (15).
The present invention is directed to a method of control

their entirety.
BACKGROUND OF THE INVENTION

ling transcriptional expression of a gene by a multi-faceted
epigenetic approach. That is, the gene of interest is tran

1. Field of the Invention
The present invention relates to a method for expressing
a gene product that could not be expressed because of

ture Without mutating the bases in the DNA. Several
examples of epigenetic modi?cations of the chromosome are
included in the invention, Without limitation. Administration

scriptionally regulated by modifying the chromosome struc

blockage occurring in a regulatory region of the gene. The

of butyrate, for example, results in the acetylation of his

present invention also relates to a method of restoring iodide

tones, thereby resulting in a more “open” chromatin struc

transport in cells defective in iodide transport. The present

ture facilitating transcriptional activation (50452). Phospho

invention is also directed to a method of treating tumors by

expressing tumor speci?c therapeutic response element in a

rylation of the nucleosome similarly alters the chemical and
20

physical properties of the nucleosome, thereby alloWing

cancerous cell in Which the response element Was blocked

greater or lesser access to a speci?c trans- acting factor that

from expression.
25

may bind to a speci?c region on the DNA (55456). Also,
administration of certain critical amounts of endogenous or
exogenous DNA binding agents, such as polyamines, cause
the level of transcriptional activity of a gene to alter in part
because of the change in the chemical and physical proper
ties of the modi?ed nucleosome (53454). Thus, it can be
seen that the methods of demethylating or inhibiting methy

30

illustration of transcriptional regulation engendered by epi

2. Brief Description of the Related Art
The initial step in the synthesis of thyroid hormone is the
active transport of iodide, mediated by the sodium-iodide
sympor‘ter (NIS) located in the basolateral membrane of

thyroid follicular cells (1). This iodide-concentrating ability
of thyroid follicular cells is exploited for the treatment of

differentiated thyroid epithelial carcinomas, using therapeu
tic dosages of I-131. Loss of iodide concentrating ability, in
the face of distantly metastatic disease, results in signi?cant
morbidity and mortality for around 10% of patients With
differentiated thyroid cancers (2). In addition, anaplastic

lation of DNA, as exempli?ed herein, serves as merely an

genetic modi?cation of chromosomes.
In the present invention methylation of the characterized
hNIS promoter, and potentially regulatory doWnstream
regions, and their correlation With loss of hNIS mRNA

thyroid cancers, Which are unable to take up radioactive

iodide and do not respond to systemic chemotherapies, are

invariably fatal.

expression, as Well as clinical loss of iodide uptake, in
samples of thyroid tumor tissues Were tested. In addition,

The complementary DNA sequence for human NIS
(hNIS), as Well as the exon-intron organization, have been

using human thyroid carcinoma cell lines and putative
demethylation agents, the reversibility of loss of hNIS

revealed by Smanik et al (3,4). The cloning and character
iZation of a 1.3 kb region of the upstream regulatory region

35

40

mRNA expression and functional activity, measured as
iodide uptake Were evaluated.

Was reported and a minimal essential hNIS promoter that

shoWs tissue-speci?c expression in a human thyroid cell line
Was de?ned (5). Other investigators have further evaluated
hNIS promoter constructs (6,7). It is possible that alterations
in hNIS expression, responsible for loss of iodide-concen
trating ability in human thyroid cancer metastases, may

SUMMARY OF THE INVENTION

The present invention is also directed to a method of
45

expressing a tumor speci?c therapeutic response element in
a cancerous cell in Which the response element Was blocked

correspond to changes in hNIS promoter activity. This may

from expression, comprising the step of administering an

be similar to the loss of E-cadherin expression demonstrated

unblocking agent to the cancerous cell harboring a gene

in human thyroid cancer cell lines, correlating to methyla
tion of CpG islands in the E-cadherin promoter (8). Since the

encoding the response element, thereby resulting in the
50

expression of the response element.

hNIS promoter has CpG-rich regions, as Well as additional

The gene of interest may be a gene that is endogenous to

CpG islands doWnstream from the transcription start site,
DNA methylation may be responsible for alterations in hNIS
expression. The DNA sequence corresponding to the mini
mal essential promoter of the gene encoding hNIS has been
reported (49). The contents of this reference are incorporated
herein by reference in their entirety.

the cancerous cell, or may be exogenous to the cancer cell,

as introduced to the cancer cell by transfection technique, for
55

human sodium-iodide sympor‘ter (hNIS).

Nearly half of all human genes have CpG islands asso

ciated With transcriptional start sites. Unmethylated CpG
islands are seen in highly transcribed genes, While heavily

60

methylated CpG islands inhibit transcription (9). Although
overall DNA methylation is often decreased in cancers, CpG
islands in critical gene promoter regions can become hyper

methylated, resulting in loss of gene expression (10). Such
methylation may be effective in silencing gene expression
despite variable degrees of CpG site methylation from 20 to
100% (11). Laboratory and clinical studies have suggested

example. Preferably, the gene encodes a sodium-iodide
sympor‘ter (N IS). More preferably, the gene may encode a
The cell may be any cancerous cell, but is preferably a
thyroid-derived cell. More preferably, the cells are dedilfer
entiated. In the present invention, a tumor speci?c therapeu
tic response element that Was turned off during dedilferen
tiation is caused to be re-expressed. The tumor speci?c
therapeutic response element may be a tumor speci?c anti
gen that may serve as a target for a therapeutic antibody, or

65

it may be an iodine transporter such that radioactive iodine
may be captured and retained in the cancerous cells. The

tumor speci?c therapeutic response element may be any
factor that is speci?cally expressed by cancerous cells and

US 7,029,879 B1
3

4

may serve as a speci?c target for therapy, and therefore is not

speci?c therapeutic response element can occur in a variety

box-like element. The shaded box (P) denotes the region of
the hNIS promoter chosen for methylation analysis. The
open box (L) and the solid box (C) denote the leader and
coding regions, respectively, of the ?rst exon Which Were

of Ways. One of these Ways is through DNA methylation of

analyZed for methylation status.

certain sequence in or near the regulatory region, the pro

FIG. 2 shoWs hNIS mRNA expression in tall-cell papil
lary thyroid carcinoma. RT-PCR products Were resolved on
a 2% agarose gel and visualiZed by ethidium bromide
staining. PCR substrates are: Lane 1, no cDNA (negative

limited to the particular forms exempli?ed herein.
The blockage of transcriptional activation of the tumor

moter, or the coding sequence. Preferably, CpG islands that
may be present are the sites of methylation. The present
invention exempli?es demethylation as a method of activat
ing transcription of a gene. But the invention is not limited
to the demethylation method alone. Other methods include

control); lane 2, normal thyroid (positive control); lanes 3*7,
tall-cell papillary thyroid carcinomas (samples 11*15, Table

inhibiting the methylation of DNA sequences. The demethy

1); and lane 8, GIBCO-BRL 1 kb-plus DNA ladder.
FIG. 3 shoWs methylation analysis of the hNIS promoter
in proximity to TATA box (Region P). Products of methy
lation speci?c-PCR analysis of sodium bisul?te modi?ed
genomic DNA from thyroid tumors using a methylation

lating agent may be any chemical or enZymatic compound or

mechanism that demethylates nucleic acids, and is prefer
ably, but not limited to, dimethylsulfoxide, sodium butyrate,
phenylacetate, or 5-aZacytidine. The demethylating agent
may also include a compound that inhibits DNA-methyl

speci?c primer pair (MET) and non-methylation-speci?c

transferase activity. Furthermore, the unblocking agent may

primer pair (UNMET) Were electrophoresed on an agarose
gel in adjacent lanes. Lanes 1 and 22: GIBCO-BRL 1 kb plus

include a compound that directly inhibits methylation of a
DNA sequence, or indirectly inhibits methylation by an

20

agent that depletes polyamines. Preferably, the agent inhibits
the synthesis of polyamines include, but not limited to,

di?uoromethylomithine(DFMO) and adenosyl-1,8-diamino
3-thio-octane.
The present invention is also directed to a method of
restoring iodide transport to dedifferentiated thyroid cancer

25

cancer samples 11 through 16, respectively (Table 1). Lane
pairs starting With 14 through 20 represent the reaction pairs

for anaplastic carcinoma (Table 1, Sample 22), negative
control (no template DNA), normal thyroid and pooled
human leukocyte DNA, respectively.

cells comprising the step of administering a demethylating
agent in an amount effective to transcriptionally activate a

tumor speci?c therapeutic response element in a cell that is

defective in iodide transport. Preferably, the tumor speci?c
therapeutic response element is the sodium iodide sym

DNA ladder; lanes 2 through 21 (even numbered lanes
contain the 151 bp UNMET product and odd numbered
lanes contain the 143 bp MET product). Lane pairs starting
With 2 to 12 represent the reaction pairs of tall cell papillary

30

FIGS. 4a, b. shoWs re-expression of hNIS mRNA in
thyroid cell lines. Follicular adenoma cell line, KAKI (a).
KAK-l cells Were treated in triplicates, With 5-aZacytidine

porter.

as described. The RT-PCR products Were resolved on a 2%

Another object of the invention is to provide a demethy
lating or methylation inhibiting agent that can transcription
ally activate or unblock the expression of the trans- acting
factor speci?c for the regulation of the speci?c therapeutic

agarose gel and visualiZed by ethidium bromide staining.

response element. This further extends to the expression of
other trans- acting factors in the regulatory cascade.
The present invention is also directed to a method of
treating a tumor by expressing a tumor speci?c therapeutic

lane 1. no cDNA; lane 2 to 4. untreated; lanes 5 to 7. 0.5 uM
35

GIBCO-BRL 1 kb plus DNA ladder. Papillary carcinoma
cell line, NPA’87 (b). NPA’87 cells Were treated in tripli
cates, With sodium butyrate or 5-aZacytidine as described.
40

The RT-PCR products Were resolved on a 2% agarose gel

and visualiZed by ethidium bromide staining. lane 1.
GIBCO-BRL 1 kb plus DNA ladder; lane 2. normal human

response element in a cancerous cell in Which the response

element Was blocked from expression, Which comprises the
steps of:
a) administering an unblocking agent to the cancerous cell
harboring a gene encoding the response element,

5-aZacytidine for 3 days (added each day); lanes 8 to 10. 1.0

uM 5-aZacytidine for 3 days (added each day); lane 11.

thyroid; lane 3 to 5. untreated; lanes 6 to 8. 1.0 mM sodium

butyrate for 3 days; lanes 9 to 11. 1.0 uM 5-aZacytidine for
45

thereby resulting in the expression of the response
element; and
b) administering a therapeutic substance to target said
tumor speci?c therapeutic response element.

3 days (added each day).
FIGSS. 5a, b. shoWs restoration of iodide uptake in
neoplastic thyroid cell lines. The uptake values are normal
iZed for cell viability, as determined by the MTT assay in a

the referenced draWings attached hereto and the claims

parallel set of plates. Follicular adenoma cell line, KAK-l
(a). The KAK-l cells Were treated With 5-aZacytidine and
the iodide uptake Was measured, in quadruplicates, as
described. Papillary carcinoma cell line, NPA’87 (b). The

appended hereto.

NPA’87 cells Were treated With sodium butyrate or 5-aZa

These and other objects of the invention Will be more fully

50

understood from the folloWing description of the invention,

cytidine and the iodide uptake Was measured, in quadrupli
BRIEF DESCRIPTION OF THE DRAWINGS

55

cates, as described.

The present invention Will become more fully understood

FIGS. 6 aid. shoWs methylation analysis of hNIS gene
regions in cell lines re-expressing hNIS mRNA. Products of

from the detailed description given hereinbeloW, and the
accompanying draWings Which are given by Way of illus

methylation speci?c-PCR analysis of sodium bisul?te modi
?ed genomic DNA, from thyroid cell lines, using tWo

tration only, and thus are not limitative of the present

60

invention, and Wherein;
FIG. 1 shoWs CpG dinucleotide frequency in the hNIS
promoter region. The DNA sequence of the hNIS promoter
and its contiguous transcribed region (up to the ?rst intron),
Was assessed by computer analysis. Nucleotide positions are
in reference to the adenosine residue of the ATG translation
start site. The bold arroW indicates the position of a ‘TATA’

65

methylation-speci?c primer pairs (MET for regions L and C)
and tWo corresponding non-methylated-speci?c primer pair
(UNMET for regions L and C) Were electrophoresed on an
agarose gel in adjacent lanes. In all gels, lanes 1 and 22:
GIBCO-BRL 1 kb plus DNA ladder; lanes 2 through 7:
triplicate pairs of cell lines under basal conditions; lanes 8
through 19: triplicate pairs of cell lines in tWo different
treatment conditions; lanes 20 and 21: negative controls

US 7,029,879 B1
5

6

Without template DNA (all even numbered lanes contain the
respective UNMET products and odd numbered lanes con
tain the corresponding MET products). Cell line KAK-l

gained “Weak” uptake) (29). A case report suggests a posi
tive response to similar treatment in a single patient (30).
Alternatively, a minimal enhancement of iodide uptake With
gamma interferon Was suggested in several human thyroid

studied With primer pairs speci?c for region L (a). Treatment
conditions in lanes 8413 and lanes 14419 include 5-aZacy

cancer cell lines in vitro (31). The mechanism for effects on

tidineat 0.5 HM and 1.0 uM, respectively. Cell line KAK-l

studied With primer pairs speci?c for region C (b), With

iodide transport is unknoWn for both of those agents
although they suggest that loss of hNIS activity may be a

conditions identical to (a). Cell line NPA’87 studied With

reversible phenomenon.

primer pairs speci?c for region L (c). Treatment conditions

In vieW of the multiplicity of mechanisms causing loss of

in lanes 8413 and lanes 14419 include sodium butyrate at 1.0

mM and 5-aZacytidine at 1.0 uM, respectively. Cell line

iodide transport, the inventors further evaluated the sub set of
tumors With apparent hNIS transcriptional failure and the

NPA’87 studied With primer pairs speci?c for region C (d),

relationship to CpG island methylation in the region of the

With conditions identical to (c).

hNIS promoter. This Was of particular importance in tall-cell
variant papillary thyroid cancers since nearly half of such
patients lose clinical iodide transport (32,33), and the inven

DETAILED DESCRIPTION OF THE
INVENTION

tors shoW this to be a consequence of hNIS transcriptional

failure. The ability of 5-aZacytidine to induce hNIS mRNA,
As used herein, “block”, “blocking” or “blockage” means

as Well as iodide uptake, in thyroid carcinoma cell lines

the inhibition or transcription of a gene of interest. The

devoid of basal hNIS mRNA expression, further implicated

inhibition includes, but is not limited to, methylation of
certain regions on the gene of interest. The region methy
lated on the gene includes the promoter, other regulatory
regions, and the coding sequence. It is to be understood that
the term “blockage” encompasses inhibition of a gene’s

20

methylation as a likely mechanism. In these cell lines,
reversal of basal methylation of the L and C regions
appeared associated With de novo induction of hNIS expres
sion. On the other hand, lack of expression of hNIS mRNA

expression by any means. This includes the context of a gene

25

to be assuredly explained by such methylation patterns. Part

in tall-cell variant papillary carcinoma tumors Was not able

of interest not being expressed because its speci?c trans

of the reason may relate to heterogeneity of cell methylation
patterns betWeen cells in the same culture. This may relate

acting factor is either not made or is non-functional.

As used herein, “unblock(s)” means the transcriptional

to the heterogeneity of hNIS protein expression demon
strated in normal and malignant thyroid tissues (34,35). A

activation or expression of a gene Which Was previously

inhibited from being expressed. The activation may be
caused by, but is not limited to, demethylation or inhibition
of methylation of the relevant regions on the gene.
As used herein, “regulatory sequence” or “regulatory

30

Likewise, tumor tissue samples are inherently heteroge
neous as mixtures of tumor cells, ?broblasts, endothelial

region” refers to a non-coding portion of a gene Which

regulates activation or expression of the gene product. The
regulatory sequence may include, but is not limited to, the

similar mechanism has been invoked for expression of
p16 a in thyroid carcinoma cell lines and tumors (36).

35

cells, smooth muscle cells, and in?ltrating host immune
cells. It is also possible that the speci?c sites of methylation

promoter, as Well as certain DNA sequences upstream of the

responsible for loss of hNIS transcription, in or near the
hNIS gene, may be different from the particular sites ana

promoter that are cis- acting regions for binding by trans

lyZed in this study.

acting factors. Regulatory sequences may exist near or at the
doWnstream end of the gene, or even in the middle of the
gene in the form of introns.

Alternative explanations for loss of hNIS mRNA expres
40

Treatment of metastatic thyroid carcinoma requires effec
tive systemic agents. Due to the absence of applicable

chemotherapeutics, radioiodine therapy is the only ef?ca
cious modality. The failure to respond to radioiodine por
tends grave consequences and is an appropriate target for
correction. Loss of hNIS gene expression appeared a likely
cause for loss of iodide concentrating ability; hoWever the

45

inventors have demonstrated that some thyroid cancers

maintain expression of hNIS mRNA despite loss of function,
suggesting diverse pathophysiology. This Was of particular

50

carrying the chloramphenicol acetyltransferase (CAT) gene
55

Some investigators have attempted to restore iodide

uptake using retinoids. A nominal increase in iodide uptake

With only one such patient re-establishing distinct iodide
uptake after cRA treatment (an additional three patients

under control of a bovine thyroglobulin promoter, CAT
expression Was limited to the thyroid glands and Was related

to thyroid-speci?c demethylation of the bovine thyroglobu
lin promoter (41). In another example, the transformed rat
60

that only 14 patients (out of 20 study patients) did not
concentrate any radioiodine in metastatic tumors at baseline,

likely feature of the hNIS gene. Since additional, possibly
complex, processes may affect post-transcriptional hNIS
function, there are multiple opportunities for gene methyla
There are several examples of DNA methylation altering
expression of thyroid-speci?c genes. In transgenic mice

of hNIS mRNA Was observed, potential mechanisms Were

activity Was reported in a thyroid follicular carcinoma cell
line UCLA RO 82 W-l (WRO82), treated With l3cis
retinoic acid (cRA) (27). Direct evidence of the effects of
cRA on re-establishing iodide uptake in dedilferentiated
follicular and papillary thyroid cancers Was ?rst reported by
Simon et al (28). The latest details of their study revealed

sion With indirect loss of hNIS mRNA expression. This Was
indicated by the KAT-5 and KAT-l0 responses to 5-aZacy
tidine treatment With acquisition of parallel TTF-l and hNIS
mRNA expression. Failure to express suf?cient TTF-l and
PAX-8 can result in decreased activity of the thyroglobulin
gene promoter in human thyroid carcinoma cells (37), a

tion to reduce iodide transport.

surprise for anaplastic carcinomas since these tumors do not
have clinical iodide uptake (5). In those tumors in Which loss

explored, focusing on reversible etiologies.

sion may relate to methylation of thyroid-speci?c transcrip
tion factor genes causing loss of transcription factor expres

thyroid cell line, FRT, is unable to express its native TSH
receptor gene, consequent to methylation of its promoter
(42). Avvedimento et al (43,44) have shoWn that transfor
mation of a rat thyroid cell line, Which activated the RAS
oncogene, resulted in loss of activity of the thyroglobulin
gene promoter, as Well as loss of expression of a thyroid

65

speci?c trans-acting factor (presumably TTF-l). Treatment
With 5-aZacytidine restored both TTF-l expression and
thyroglobulin promoter activity. Such cases provide evi

US 7,029,879 B1
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dence that thyroidal tissues use methylation as a regulatory

Cell Culture

mechanism for gene expression, particularly in transformed

Cell lines, for evaluation of iodide-uptake and hNIS
expression, Were groWn in phenol-red-free RPMI 1640 With
5% fetal bovine serum (FBS), 100 nM sodium selenite and

phenotypes.
The potential to restore iodide transport in dedilferenti

0.1 nM bovine TSH (basal medium) (20). They Were plated
at a density of 345x104 cells/9.4 cm2, in triplicate in basal
medium, and groWn for 243 days at 37° C. in 5% CO2. They
Were treated With dimethylsulfoxide (DMSO, 25 uM daily
for 3 days), sodium butyrate (0.5 or 1.0 mM), phenylacetate

ated thyroid carcinomas With demethylation agents suggests
clinical application. The degree of hNIS expression needed
to deliver tumoricidal radioiodide is not clear. Normal

thyroid tissue, stimulated by TSH, concentrates radioiodide
at 1% of the administered dose per gram of tissue. Dilfer
entiated thyroid cancer metastases typically concentrate
radioiodide at 0.06 to 0.3% of the administered radioiodide
dose per gram of tumor (45). Calculations of the degree of

(pH 7.0, 5 or 10 mM) or 5-aZacytidine (0.5 or 1.0 uM, in 25
uM DMSO, daily for 3 days) until control cells Were 80%
con?uent (344 days), then changed to fresh basal medium
and groWn for an additional 24 hrs.

radioiodide uptake and biologic residence time needed for
sufficient therapy of thyroid cancer suggest that (employing
can be achieved despite an uptake of only 0.1%, using
administered activities of 300 mCi (46). Use of radioiodide

Analysis of CpG Content in the hNIS Gene Sequence
The hNIS gene sequence of the 5' ?anking region (5) and
the contiguous transcribed region extending up to the ?rst
intron (3,4), Was analyZed using WINDOW and STATPLOT

dosimetry analysis, to verify upper safety margins of admin
istered doses, may permit therapy doses exceeding 600 mCi

Wis.) to denote CpG dinucleotide frequencies.

an effective half-life of at least 4.5 days) tumor destruction

computer programs (Genetics Computer Group, Madison,
20

(47) so that tumors With less than 0.05% uptake may respond
to treatment. For this reason, restoration of hNIS activity

Nucleic Acid Isolation and Ampli?cation
Total RNA and genomic DNA from: normal human

sufficient to treat thyroid cancer does not require hNIS
expression to the levels seen in normal human thyroid
follicular cells.
Effective radioiodide therapy requires more than a func
tional hNIS gene. There should be sufficient expression of
TSH receptors and doWnstream signal transduction machin
ery to amplify hNIS expression When TSH levels rise. In

thyroid, thyroid tumors, and cell lines (treated With agents
described above), Were isolated by the acid-guanidinium
phenol-chloroform method (21). All surgical samples Were
snap-froZen and stored at —80° C. until processed by homog
eniZation in TriZol reagent (Life Technologies, Gaithersburg,

addition, failure to organify radioiodide compromises I-131
residence time in thyroid carcinoma cells, permitting radio

25

Md.) While still froZen. Complementary DNA (cDNA) Was
synthesiZed from 1.0 ug of total RNA using MMLV reverse
30

Palo Alto, Calif.). Each 50 pL polymerase chain reaction
(PCR) vessel contained: 60 mM Tris HCl, pH 9.0, 15 mM
ammonium sulfate, 3.5 mM MgCl2 (1.5 mM for hTTF-l),

iodide ef?ux and insu?icient radiation delivery. This Was
seen by Shimura et al (48) When they transfected trans

250 uM dNTPs (Boehringer-Mannheim, Indianapolis, Ind.),

formed rat thyroid cells, lacking endogenous NIS expres
sion, With rat NIS cDNA and restored radioiodide uptake.
The Shimura et al. reference is incorporated herein by

35

in xenografts of these cells, they Were unable to obtain
tumoricidal effects due to rapid radioiodide ef?ux from lack
40

able to restore additional critical functions, such as organi

?cation, doWnstream from iodide transport.
The folloWing examples are offered by Way of illustration
of the present invention, and not by Way of limitation.
45

EXAMPLES

PCR primers (upstream 5' to 3'/doWnstream 5' to 3', in all
cases) used for ampli?cation Were, for hNIS (5), CTGC
CCCAGACCAGTACAT GCC (SEQ ID NO. 1)/TGACG
GTGAAGGAGCCCTGAAG (SEQ ID NO. 2) (to amplify a

coding region spanning four introns (4) yielding a 303 bp
product from cDNA) and for Pax-8, AAGTCCAGCAT
TGCGGCACA (SEQ ID NO. 3)/GAGGGAAGTGCT
TATGGTCC (SEQ ID NO. 4)((22) to amplify a 329 bp
product). Ampli?cation conditions for hNIS and Pax-8 Were:
denaturation (95° C.><5 min); 40 cycles of 20 sec at 95° C.

Example 1
Materials and Methods

0.2 uM each primer pair, 1 U AmpliTaq DNA polymerase

(Perkin-Elmer, NorWalk, Conn.), 0.2 ug TaqStart Antibody
(Clontech) and 3% cDNA. [3-actin ampli?cation (primers,
Stratagene, La Jolla, Calif.) con?rmed cDNA integrity,
purity, and template equivalence for semiquanti?cation.

reference in its entirety. Despite high levels of I-131 uptake

of effective organi?cation. Demethylation therapy may be

transcriptase (RT) With random-hexamer primers (Clontech,

50

and 60 sec at 68° C.; folloWed by extension at 72° C. for 3
min. The hTTF-l product Was ampli?ed With intron span

ning primers, GCCGTACCAGGACACCATGAG (SEQ ID
Cell Lines and Human Tissues
Human thyroid cell lines used Were: MRO87 and WRO82

(both follicular carcinomas), NPA’87 (papillary carcinoma),

NO. 5)/CAGGTACTTCTGTTGCTTGAAG (SEQ ID NO.
6), Which amplify a 263 bp fragment. The conditions Were:
55

KAT-5 and KAT-10 (both papillary carcinomas (16)),
KAK-l (benign follicular adenoma (17)), and KAT-7 (be
nign follicular hyperplasia). Cultures Were previously
treated With medium containing D-valine (18) and cis-4
hydroxy-L-proline (19) to ensure the absence of ?broblasts.
Human thyroid tissues Were obtained from fresh surgical

agarose gels and visualiZed by ethidium bromide staining.

Methylation-Speci?c Polymerase Chain Reaction (MS
60

PCR) Analysis
This method utiliZes PCR primer pairs to distinguish
methylated from unmethylated DNA in bisul?te-modi?ed
target DNA, in Which bisul?te converts unmethylated
cytosines to uracil (23,24). Genomic DNAs, from normal

samples (approved by University of Kentucky Institutional
RevieW Board). Some tumor samples Were supplied by the
Cooperative Human Tissue NetWork (Philadelphia, Pa.) and
some Were obtained from surgical samples at the Clinical

95° C. for 5 min; 45 cycles of 95° C. for 20 sec, 60° C. for
60 sec, and 72° C. for 30 sec; folloWed by extension at 72°
C. for 3 min. The RT-PCR products Were resolved on 2%

65

and tumoral human thyroid tissues and cell lines, Were

Center, National Institutes of Health, Bethesda, Md. (under

isolated by standard techniques (21) and 1.0 ug aliquots

approved protocol).

Were denatured by NaOH (10 min at 37° C.), then treated

US 7,029,879 B1
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With 10 mM hydroquinone and 3.0 M sodium hisul?te (pH
5.0 under mineral oil for 16 hrs at 50° C.). Modi?ed DNA

This is based upon the assumption that tumor redilferentia

tion, spontaneously restoring loss of iodide uptake, is far less

Was puri?ed on a resin column (Qiagen) and further treated

common than tumor dedi?‘erentiation. The absence of radio

With 0.3 N NaOH for 5 min prior to ethanol precipitation.
The PCR mixture contained 16.6 mM ammonium sulfate, 67

metastases Was presumed to re?ect loss of radioiodine

iodine uptake in palpahle or radiologically discernihle tumor

mM Tris-HCl (pH 8.8), 6.7 mM MgCl2, 10 mM [3-mercap
toethanol, 1.25 mM dNTPs, 0.2 ML TaqStart antibody, 1 U

uptake in the primary tumor sample. This designation is
likely correct; hoWever it is possible that metastases may
have less functionality than their parent tumors. In the
absence of persistent tumor metastases, the assessment of
radioiodine uptake Was not possible. Some tumor samples

AmpliTaq DNA polymerase, 10 pmoles each of sense and
antisense methylation-speci?c primers, and 50 mg of hisul
phite-modi?ed DNA target. Primers used for analysis of the
hNIS promoter CpG island methylation Were selected for

were obtained from recurrent tumors Which had been docu

cytosine-rich regions, containing CpG dinucleotides near the

mented to lack radioiodine uptake on the basis of previous

3' end of the primers, hNIS-MET-P (sense, 5' to 3', TTAG
GTTTGGAGGCGGA GTCGC (SEQ ID NO. 7) and anti
sense,

5'

to

3',

ACCGACTATCTATCCCT

whole body scanning.

CTC

CCTAAACG) (SEQ ID NO. 8) for a 143 hp product from
methylated DNA and hNIS-UNMET-P (sense, 5' to 3',
TTGTTTTTAGGTTTGGAGGTG GAGTTGT (SEQ ID
NO. 9) and antisense, 5' to 3', CAACCAACTATCTATC
CCTCTC CCTAAACA) (SEQ ID NO. 10) for a 151 hp
product from unmethylated genomic DNA. Additional sets
of primers Were similarly designed to analyZe further doWn

Example 2
Results
20

Promoter

The hNIS promoter region, and its contiguous doWn

stream elements. They Were: hNIS-MET-L (sense, ATA

stream regions up to the ?rst intron, Were analyZed for the

GATAGATAGTAGGGGCGGAC (SEQ ID NO. 11) and

antisense, GACCT CCATAAAAACGAATACG) (SEQ ID
NO. 12) for a 265 hp product, With hNIS-UNMET-L (sense,
TAGGATAGATAGATAGTAGGGGTGGAT (SEQ ID NO.
13), and antisense, CTCCACAACCTCCATAAAAA
CAAATACA) (SEQ ID NO. 14), for a 275 hp product,
hNIS-MET-C (sense, AGGTCGTGGAGATCGGGGAAC
(SEQ ID NO. 15) and antisense, ACGATAAACCTCCGAC

GACACG) (SEQ ID NO. 16) for a 242 hp product, and
hNIS-UNMET-C (sense, TTATGGAGGTTGTGGAGAT
TGGGGAAT (SEQ ID NO. 17), and antisense, CATAA
CAATAAACCTCCAACAACACA) (SEQ ID NO. 18), for

CpG Dinucleotide Distribution in the Context of the hNIS

25

presence of CpG islands. The frequency plot (FIG. 1) shoWs
a region of the promoter, surrounding the transcription start
site (5) and extending upstream for about 100 base pairs, to
he rich in CpG dinucleotides (region P). This Was the only
upstream region in the characterized promoter that Was

30

CpG-rich. Sequence comparison revealed that this region
shared signi?cant homology to the rat NIS promoter region
(26). This region Was selected for analysis of methylation
status in clinical tumors and cell lines. Additional CpG-rich
sequences are present doWnstream from this region, extend

35

ing to the ?rst intron. Regions L and C, selected for

a 252 hp product. The ampli?cation conditions Were: Taq
polymerase activation at 95° C. for 5 min, 40 cycles of:

methylation analysis, corresponded to CpG-rich sequences

denaturation at 94° C. for 20 s, annealing at 60° C. for 30 s
and polymeriZation at 72° C. for 30 s. MS-PCR products

the ?rst exon.

Were resolved by agarose gel electrophoresis and visualized
by ethidium bromide staining and UV transillumination.

in the hNIS leader and coding regions, respectively, Within
40

Thyroid Carcinoma
Primary thyroid tumors Were analyzed by RT-PCR for the
expression of hNIS mRNA (FIG. 2 and Table 1). Messenger

Iodide Uptake Assay
Cell lines, treated With differentiation agents and control
cultures, Were Washed With 2 mL of buffer containing: 10
mM HEPES (pH 8.3), 5.5 mM glucose, 5.4 mM KCl, 1.3
mM CaCl2, 0.4 mM Na2HPO4, 0.44 mM KH2PO4, and
either 137 mM NaCl (Buffer A) or 100 mM choline chloride

RNA for hNIS Was poorly expressed in all of six tall cell
45

cells Were Washed once With Buffer A, lysed With 0.1 M

50

mRNA expression. Among the 19 tumor samples Which
were able to he assessed for clinical radioiodide uptake, 13
cases exhihited concordance of hNIS mRNA expression

uptake activity, using 3-(4,5-dimethylthiaZol-2-yl)-2,5
55

A, under corresponding conditions, to account for non

follicular carcinoma) there Was no detectable radioiodine
60

Assessment of radioiodine uptake in clinical tumor
samples was based upon the results of I-131 whole body
scans (using 5 mCi I-131 tracer doses), performed 648

Weeks after excision of the primary tumor during surgical
thyroidectomy. The presence of radioiodine uptake in meta

With whole body scanning (7 With concordant positive
?ndings and 6 With concordant negative ?ndings). In 6 cases
(dispersed between all of the tumor histologies except

B were subtracted from counts of cells incubated in Buffer

speci?c binding of radioiodide.
Clinical Radioiodine Uptake

10 typical papillary carcinomas (variahle levels of expres
sion), and in both of tWo anaplastic thyroid carcinomas. TWo
of the three Hiirthle cell carcinomas Were negative for hNIS

NaOH and gamma counted (5). A parallel set of dishes,
similarly plated and treated, Were used for normaliZation of
diphenyltetraZolium hromide (MTT) assay (25) as an index
of cell viability. Gamma counts of cells incubated in Buffer

papillary carcinomas, ranging from undetectable in four
tumors and moderately positive in tWo tumors (?ve cases
shoWn in FIG. 2). In contrast, hNIS mRNA expression Was
clearly detectable in both of the follicular carcinomas, 9 of

(Buffer B). After a 60 min incubation in the same buffer

supplemented With Na(125 I) (1.0 uCi/ 2 mL) and 1.0 uM NaI,

hNIS mRNA expression and Clinical Iodide Uptake in

uptake on whole body scanning despite detectahle hNIS
mRNA in the tumor sample. Analysis of thyroid transcrip
tion factor mRNA expression in these discordant cases
revealed that all expressed PAX-8 and only 2 of the 6 cases
expressed TTF-l. Since only one of 7 tumor samples, With

65

concordant positive radioiodine uptake and hNIS mRNA
expression, lacked TTF-l mRNA expression, loss of this

static tumor deposits Was presumed to he indicative of

factor may contribute to loss of hNIS function, but is not

positive radioiodine uptake in the primary tumor sample.

totally explanatory.
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Methylation Status and hNIS mRNA Expression in Thyroid

revealed that the P region Was unmethylated under all
conditions, basal or otherWise. Methylation of the L and C
regions, under basal conditions, Was clearly evident in all

Cancers

The NIS promoter Was only faintly methylated in normal
human thyroid tissues and in pooled human White blood

four cell lines. The PCR product speci?c for unmethylated

cells. As described in the previous section, hNIS mRNA Was
undetectable in four out of six tall cell papillary carcinomas
and loW in the other tWo. In all of these six cases the hNIS

DNA in the L and C regions Was undetectable or merely

faintly present in the same cell lines, suggesting that the cell
populations Were homogeneously methylated in these

promoter (region P) Was strongly methylated (FIG. 3 and

regions. Treatment With 5-aZacytidine Was associated With
decreased methylation at the L and C regions in all four cell

Table 1). Region L Was methylated in all but one case,

although displaying loWer signal intensities for the methy
lated ampli?cation product. A CpG-rich segment of the

lines, as evidenced by decreased intensity of the methyla
tion-speci?c PCR products and de novo or increased expres

coding region (Region C) displayed heterogeneous methy

sion of the corresponding unmethylated PCR products to
equal or greater intensity than the methylated product bands.

lation among tall cell tumors, Without any particular corre
lation to hNIS mRNA expression. However, of the ten
papillary thyroid tumors, there Was no apparent association

The susceptibility of KAT-5 and KAT-10 cells to the dem

ethylation effects of 5 -aZacytidine in the C region appeared
less than that of the L region. Although sodium butyrate

of methylation, in Regions P, L, or C, With loss of hNIS
mRNA expression. Likewise, although both follicular car
cinomas expressed hNIS mRNA, they each shoWed different
methylation patterns betWeen the regions. All of the three
cases of Hiirthle cell carcinoma had unmethylated hNIS

treatment Was associated With re-expression of hNIS mRNA

in both NPA’87 and KAT-10, With phenylacetate having a

lesser effect in KAT-5, analysis of methylation patterns of
20

the NPA’87 and KAT-10 response to sodium butyrate failed
to demonstrate effects on altering baseline methylation pat
terns in all three regions.
In the three cell lines that failed to express hNIS mRNA,

25

phenylacetate (MRO87, WRO82, and KAT-7), baseline

promoter regions, and variably methylated L and C regions,
but only one of them expressed hNIS mRNA.
Treatment of Thyroid Carcinoma Cell Lines to Restore
Expression of hNIS mRNA and Effect on Iodide Uptake

Seven human thyroid neoplastic cell lines, devoid of hNIS
mRNA expression under basal monolayer conditions, Were
treated With putative chemical demethylation agents in an
attempt to restore hNIS expression. These cell lines Were

derived from three papillary carcinomas (NPA’87, KAT-5,
and KAT-10), tWo follicular carcinomas (WRO82 and
MRO87) and tWo benign follicular neoplasms (KAK-l and
KAK 50) (5). Three different demethylation or redilferen
tiation agents (viZ., sodium butyrate, phenylacetate and
5-aZacytidine) Were tested on each of 7 cell lines for their

ability to induce re-expression of hNIS mRNA. Re-expres

30
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sion of hNIS mRNA Was achieved in all three of the

papillary cell lines and one of the benign follicular
adenomas under at least one treatment condition (Table 2).
FIG. 4, a and b, demonstrate the hNIS mRNA re-expression
in cell lines KAK-l and NPA’87, respectively.
To investigate Whether re-expression of NIS mRNA is
su?icient to restore hNIS function, i.e., iodide uptake, We

methylation pattern analysis revealed that region P Was not
methylated While regions L and C Were homogeneously
methylated. Treatment With 5-aZacytidine did not affect the
baseline demethylated status in the P region of these cell
lines; hoWever the results in the L and C regions Were
different than seen in the four responding cell lines. Region
C appeared methylated under basal conditions in the three
cell lines (analysis of WRO82 failed to reveal either methy
lated or unmethylated products) and did not become dem
ethylated in response to 5-aZacytidine, except for minimal
detection of an unmethylated product for WRO82 cells (a

methylated product becomes clearly visible). The demethy
lation response, to 5-aZacytidine in the L region, Was similar
40

in both responsive and non-responsive cell lines. The failure

of 5-aZacytidine to effectively demethylate the C region
distinguished cell lines Which failed to re-express hNIS

mRNA from those Which regained such expression.

treated responding cells under the same conditions as used

to restore mRNA expression and analyZed for 125I uptake
activity. Of the four responding cell lines tested, there Was

despite treatment With 5-aZacytidine, sodium butyrate, or

Comparison of hNIS Re-expression to Expression Patterns
45

of TTF-1 and PAX-8

a greater than tWo-fold increase in uptake in KAK-l cells

To explore the possibility that re-expression of hNIS

(derived from a benign follicular adenoma) When treated
With 1.0 uM 5-aZacytidine as compared With untreated cells

mRNA may be consequent to re-expression of one or more

transcription factor(s) RT-PCR analysis Was performed for
thyroid-speci?c transcription factors, TTF-1 and Pax-8

(FIG. 5a). HoWever, no enhancement of uptake Was seen

centrations of 5-aZacytidine (FIG. 4a). The iodide uptake

(Table 2). Pax-8 mRNA Was found to be expressed under all
conditions tested, in all of the four cell lines Which Were able
to re-express hNIS mRNA, While TTF-1 mRNA expression

activity in NPA’87 cells (derived from a papillary carci
noma) Was slightly increased With 1.0 mM sodium butyrate

NPA’87 and KAK-l (data not shoWn). Basal TTF-1 expres

using 0.5 uM 5-aZacytidine, even though re-expression of
hNIS mRNA Was comparable under the tWo different con

While 1.0 M 5-aZacytidine treatment resulted in over 15-fold

Was found even under basal conditions in the cell lines
55

differences in iodide uptake Were noted despite similar

expression of hNIS mRNA (FIG. 4b), suggesting the pos
sible contribution of some other inducible factor.

60

Restoration of Iodide Uptake and Demethylation of hNIS
Promoter

regions as studied in the tumors (Table 2). This analysis

line, hoWever sodium butyrate did not have such an effect in
either of the cell lines.

Example 3

The cell lines KAK-l, KAT-5, KAT-10 and NPA’87, in
Which hNIS expression Was restored, Were groWn under
basal and re-expression conditions and the DNA Were ana
lyZed for their methylation status at the same three gene

sion Was undetectable in cell lines KAT-5 and KAT-10,

although TTF-1 mRNA expression Was induced by 5-aZa
cytidine treatment. LikeWise, phenylacetate treatment
induced TTF-1 mRNA expression only in the KAT-5 cell

increased uptake (FIG. 5b). As in the other cell line, the
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Inhibition of Polyamine Synthesis Restores Sodium/Iodide
Symporter Gene Expression and Activity in Dedilferentiated
Thyroid Carcinoma Cell Lines
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hNIS transcriptional failure in thyroid carcinoma could be
consequent to methylation of DNA in critical regulatory
regions and could be reversed by inhibition of DNA-meth
yltransferase. Restoration of hNIS gene expression and

TABLE 1-continued
Thyroid tissue analysis

activity from direct DNA-methyltransferase inhibition by
5-aZacytidine has been shoWn. Reports suggest that decar
boxylated S-adenosylmethionine (dcSAM) is an endog

Methylation Status

enous inhibitor of DNA methylation, competing against the
methyl-donor, S-adenosylmethionine. Since dcSAM is con

sumed by synthesis of polyamines (putrescine, spermidine,
spermine) and its synthetic enzyme (adenosylmethionine
decarboxylase) is stimulated by polyamine depletion, block
ade of polyamine synthesis precipitously increases dcSAM
levels. This should block DNA-methyltransferase activity

Tumor

Sample

Histology

Number

P

L

3

+

4

—

and restore lost hNIS expression in dedilferentiated thyroid
carcinomas. To assess this, human thyroid cell lines

by Region

Clinical

hNIS mRNA Radioiodine
C

Expression

Uptake

faint

+

+

—

+

+

(NPA’87, papillary carcinoma, & KAK-l, follicular
5

—

+

+

++

NA.

6

++

—

+

++

+

7

++

+

++

+

+

8

—

+

+

+

lase, blocking putrescine synthesis) or S-adenosyl-1,8-di

9

+

++

+

—

amino-3-thio-octane (AdoDATO, at 10 or 30 uM; an ami

10

+

—

+

—

adenoma) Without basal expression of hNIS or thyroglobulin
(TG) mRNAs, Were groWn as monolayers in phenol red-free
RPMI 1640 With 10% fetal bovine serum. Starting 24 hrs

20

after plating and for 6 days (replacing media & agent every
other day), cells Were treated With di?uoromethylomithine
(DFMO, at 1 or 3 mM; an inhibitor of ornithine decarboxy
25

++

nopropyltransferase inhibitor blocking spermidine synthase
and spermine synthase). Cells Were harvested for RNA,
subjected to reverse transcriptase With random hexamer
priming for cDNA, and then polymerase chain reactions

With primers to amplify: hNIS, TG, thyroid peroxidase

30

(TPO), and [3-actin. Parallel cultures Were assessed for

Tall-cell

11

++

faint

++

—

—

variant

12

++

+

++

+

—

Papillary

13

+

+

faint

—

—

carcinoma

14

++

+

—

—

15

++

+

—

—

16

+

—

+

—

17

+

faint

++

+

N.A.

Na[l25l] uptake (RAIU) in serum-free buffer, subtracting
1251 counts in buffer With choline (100 mM) to correct for
non-speci?c counts and results normaliZed for cell density in
each condition using thiaZolyl blue (MTT) assays. In both
cell lines, DFMO and AdoDATO restored hNIS and TG

35

mRNA expression, With higher doses having greater effect.
Both cell lines had minimal basal TPO expression With each
reagent enhancing expression at every dosage. DFMO at 3
mM caused greatest increases in RAlU (>6-fold) in NPA’87
cells and 30 uM AdoDATO had the greatest response
(~5-fold) in KAK-l cells. This supports DNA-methylation

faint

Follicular
Carcinoma

—

18

—

faint

++

++

Hiirthle cell

19

—

—

+

++

—

Carcinoma

20

—

+

—

—

40

as a reversible cause of loss of iodide transport in dedilfer

entiated thyroid carcinoma and endorses polyamine inhibi
tion as a therapeutic method to restore responsiveness to

45 Anaplastic

radioiodine therapy.

Carcinoma
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++
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—

22
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—

+

+
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—

++

+*

—

++
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23

Whereas particular embodiments of this invention have
been described above for purposes of illustration, it Will be

faint
Normal

evident to those persons skilled in the art that numerous

variations of the details of the present invention may be
made Without departing from the invention as de?ned in the

50

24

Thyroid

Tissue

faint
—

25

faint

appended claims.
All of the references cited herein are incorporated by
reference in their entirety.
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TABLE 1
Thyroid tissue analysis

Methylation: ++, distinctly positive; +, moderately positive; faint, slightly
Tumor

Sample

Histology

Number

Methylation Status
by Region

P

L

C

Clinical
hNIS mRNA Radioiodine

Expression

positive; —, negative.
mRNA expression: ++, comparable to normal thyroid; +, moderate level;
—, negative.

Uptake

Clinical radioiodine uptake: +, positive tumor uptake; +*, assumed (patient
Typical

1

—

+

papillary

2

—

—

Carcinoma

—

+

++

+

—

N.A.

euthyroid); —, no tumor uptake; N.A., results not available.
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TABLE 2
Hurnan thyroid cell line analysis

Cell Line
NPA'87

KAK-l

KAT-5

KAT-10

Culture

hNIS

Speci?c 1251

Additive

mRNA

Uptake

Methylation Status
by Region
P

L

C

TTF-l

Pax-8

mRNA

mRNA

None

—

—

—

+

+

+

+

AzaC-low

—

—

nd

nd

nd

nd

nd

AzaC-high

+

+

—

—

—

+

+

NaB-loW

—

—

nd

nd

nd

nd

nd

NaB-high

+

—

—

+

+

+

+

PhAc-loW

—

—

nd

nd

nd

nd

nd

PhAc-high

—

nd

nd

nd

nd

nd

None

—

—

—

+

+

+

+

AzaC-loW

+

—

—

—

—

+

+

AzaC-high

+

+

—

—

—

+

+

NaB-loW

—

—

nd

nd

nd

nd

nd

NaB-high
PhAc-loW
PhAc-high

—
—
—

—
—
—

nd
nd
nd

nd
nd
nd

nd
nd
nd

nd
nd
nd

nd
nd
nd

None

—

—

—

+

+

—

+

AzaC-low

—

—

nd

nd

nd

nd

nd

AzaC-high

+

—

—

—

—

+

+

NaB-loW
NaB-high

—
—

—
—

nd
nd

nd
nd

nd
nd

nd
nd

nd
nd
nd

PhAc-loW

—

—

nd

nd

nd

nd

PhAc-high

+

—

—

+

+

+

+

None

—

—

—

+

+

—

+

AzaC-loW

+

—

—

—

—

+

+

AzaC-high

Lethal additive concentration for this cell line

NaB-loW

—

—

nd

nd

nd

nd

NaB-high

+

—

—

+

+

—

nd
+

PhAc-loW

—

—

nd

nd

nd

nd

nd

PhAc-high

—

—

nd

nd

nd

nd

nd

Culture Additives: AzaC, 5-azacytidine (loW, 0.5 uM; high, 1.0 uM); NaB, sodiuIn
butyrate (loW, 0.5 mM; high, 1.0 mM); and PhAc, phenylacetate (loW, 5.0 mM; high, 10

mM).

Speci?c 1251 uptake (monolayer cultures): +, positive; and —, negative.

Methylation: +, positive, —, negative.
mRNA expression (hNIS, TTF-l, Pax-8): +, positive; —, negative; and nd, not done.
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SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

l6

<2 10> SEQ ID NO 1
<211> LENGTH: 32
<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: primer
<400> SEQUENCE: l

gtcgacatgg atctgcaaac ctcgttgctg tg

32

<2 10> SEQ ID NO 2
<211> LENGTH: 32
<2 12> TYPE: DNA

<2 13> ORGANISM: Artificial Sequence
<220> FEATURE:

<223> OTHER INFORMATION: primer
<400> SEQUENCE: 2

actagttcag gtgcctttgc tttctgtcct ct

<2 10>
<211>
<2 12>
<2 13>

32

SEQ ID NO 3
LENGTH: 353
TYPE: PRT
ORGANISM: Rat

<400> SEQUENCE: 3
Met Asp Leu Gln Thr Ser Leu Leu Ser Thr Gly Pro Asn Ala Ser Asn
1
5
10
15

Ile Ser Asp Gly Gln Asp Asn Leu Thr Leu Pro Gly Ser Pro Pro Arg
20

25

30

Thr Gly Ser Val Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly
35

40

45

Thr Ile Cys Leu Leu Gly Ile Val Gly Asn Ser Thr Val Ile Phe Ala
50

55

60

Val Val Lys Lys Ser Lys Leu His Trp Cys Ser Asn Val Pro Asp Ile

Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met
85
90
95

Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly
100

105

110

Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
115
120
125

Thr Ser Thr Tyr Ile Leu Thr Ala Met Thr Ile Asp Arg Tyr Leu Ala
130

135

140

Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Met Ala
145

150

155

160

Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
165
170
175

